Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
BRTX 
BioRestorative Therapies Inc (BRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: BRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.57% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.59M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 2 | Beta 0.08 | 52 Weeks Range 0.98 - 2.55 | Updated Date 12/8/2025 |
52 Weeks Range 0.98 - 2.55 | Updated Date 12/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-18 | When - | Estimate -0.375 | Actual -0.33 |
Profitability
Profit Margin - | Operating Margin (TTM) -31432.3% |
Management Effectiveness
Return on Assets (TTM) -89.73% | Return on Equity (TTM) -207.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3178837 | Price to Sales(TTM) 25 |
Enterprise Value -3178837 | Price to Sales(TTM) 25 | ||
Enterprise Value to Revenue 1.27 | Enterprise Value to EBITDA 0.13 | Shares Outstanding 8876242 | Shares Floating 6033981 |
Shares Outstanding 8876242 | Shares Floating 6033981 | ||
Percent Insiders 21.9 | Percent Institutions 9.37 |
Upturn AI SWOT
BioRestorative Therapies Inc
Company Overview
History and Background
BioRestorative Therapies Inc. is a clinical-stage company focused on developing cell and tissue-based therapies for the treatment of degenerative diseases. Founded in 2004, the company has primarily focused on its lead product candidate, BRTX-100, for the treatment of lumbar disc disease. Significant milestones include initiating clinical trials for BRTX-100 and advancing its research and development pipeline.
Core Business Areas
- Regenerative Medicine Therapies: Development of proprietary cell and tissue-based therapies aimed at treating degenerative conditions. The core focus is on stimulating the body's natural healing processes.
Leadership and Structure
Information on the current leadership team and specific organizational structure is not readily available in a detailed public format. The company operates as a publicly traded entity, implying a standard corporate governance structure with a board of directors and executive management.
Top Products and Market Share
Key Offerings
- BRTX-100: A proprietary autologous cellular product designed to treat degenerative conditions, primarily focusing on lumbar disc disease. Market share data is not applicable as it is a clinical-stage product. Competitors in the broader regenerative medicine space include companies developing stem cell therapies, gene therapies, and advanced biomaterials for musculoskeletal conditions.
Market Dynamics
Industry Overview
The regenerative medicine industry is a rapidly growing field focused on repairing, replacing, or regenerating damaged tissues and organs. It is characterized by significant research and development investment, a complex regulatory pathway, and the potential for groundbreaking treatments.
Positioning
BioRestorative Therapies Inc. is positioned as a niche player in the regenerative medicine space, with a specific focus on autologous cell therapy for disc degeneration. Its competitive advantage lies in its proprietary technology and its clinical focus on a significant unmet medical need. However, it faces competition from other regenerative medicine approaches and traditional treatment modalities.
Total Addressable Market (TAM)
The TAM for regenerative medicine therapies, particularly for degenerative diseases like disc degeneration, is substantial and growing. While specific TAM figures for BRTX-100 are not publicly detailed, the global market for back pain treatments alone is in the tens of billions of dollars. BioRestorative Therapies Inc. is positioned to capture a segment of this market if its lead product proves effective and gains regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary cellular therapy technology (BRTX-100)
- Focus on a significant unmet medical need (lumbar disc disease)
- Clinical-stage development with ongoing trials
Weaknesses
- Clinical-stage company with no approved products
- Dependence on successful clinical trial outcomes
- Limited financial resources compared to larger biopharmaceutical companies
- Unproven market adoption for its specific therapy
Opportunities
- Potential for significant patient impact and market penetration if BRTX-100 is approved
- Expansion of the therapy to other degenerative conditions
- Partnerships or collaborations with larger pharmaceutical companies
- Advancements in regenerative medicine technology
Threats
- Failure of clinical trials to demonstrate efficacy or safety
- Regulatory hurdles and lengthy approval processes
- Competition from alternative therapies (surgical, pharmacological, other regenerative approaches)
- Reimbursement challenges for novel therapies
- Dilution from future fundraising activities
Competitors and Market Share
Key Competitors
- Companies developing stem cell therapies for musculoskeletal conditions
- Companies developing gene therapies for degenerative diseases
- Companies offering surgical solutions for disc disease
- Companies developing advanced biomaterials for spinal fusion and disc repair
Competitive Landscape
BioRestorative Therapies Inc. operates in a highly competitive landscape where established pharmaceutical companies and emerging biotech firms are vying for market share in regenerative medicine. Its advantages lie in its targeted approach to disc degeneration. However, it faces significant challenges from companies with more advanced pipelines, larger clinical trial footprints, and established commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by scientific advancement, progression through preclinical and early-stage clinical development, and fundraising efforts. Revenue growth has not been a primary indicator due to the company's stage of development.
Future Projections: Future projections are highly speculative and contingent on the successful development and regulatory approval of BRTX-100. If successful, significant growth potential exists. Analyst estimates, if available, would focus on potential market penetration and peak sales forecasts.
Recent Initiatives: Recent initiatives likely involve advancing clinical trials for BRTX-100, exploring potential partnerships, and securing necessary funding for ongoing operations and development.
Summary
BioRestorative Therapies Inc. is a clinical-stage company with a focused approach on regenerative medicine for degenerative diseases, primarily lumbar disc disease with its lead candidate BRTX-100. While it has a promising therapeutic avenue and addresses a significant unmet need, its success hinges entirely on the outcomes of its clinical trials and subsequent regulatory approvals. The company faces substantial financial risks and intense competition within the rapidly evolving biotech landscape, requiring careful navigation of funding and strategic partnerships to achieve its commercialization goals.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the U.S. Securities and Exchange Commission (SEC)
- Financial data providers (e.g., Yahoo Finance, Google Finance)
- Industry research reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investing in clinical-stage biotechnology companies carries significant risks, and investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioRestorative Therapies Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2007-07-27 | Chairman of the Board, President & CEO Mr. Lance Alstodt | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.biorestorative.com |
Full time employees 11 | Website https://www.biorestorative.com | ||
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.